Multicentre, Randomised, Double-blind, Phase III Trial to Investigate the Efficacy and Safety of Oral SHR1020 Plus Docetaxel Therapy Compared to Placebo Plus Docetaxel Therapy in Patients With Local Advanced or Metastatic or Recurrent Non Squamous Non Small Cell Lung Cancer After Failure of First Line Chemotherapy.
Phase of Trial: Phase III
Latest Information Update: 06 Mar 2017
At a glance
- Drugs Docetaxel (Primary) ; Famitinib (Primary)
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Sponsors Jiangsu Hengrui Medicine Co.
- 20 Feb 2017 Status changed from recruiting to discontinued as the sponsor initiatively closed the study.
- 15 Jul 2016 Status changed from not yet recruiting to recruiting.
- 18 May 2016 New trial record